TargetMol

Edralbrutinib

Product Code:
 
TAR-T63272
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T63272-1mg1mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63272-5mg5mg£736.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63272-10mg10mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63272-25mg25mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63272-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63272-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63272-500mg500mg£4,006.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Edralbrutinib is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and lymphatic system disorders.Edralbrutinib is used in the study of membranous glomerulonephritis and optic neuromyelitis optica.
CAS:
1858206-58-2
Molecular Weight:
489.4734
Pathway:
Angiogenesis|Tyrosine Kinase/Adaptors
Purity:
0.9947
SMILES:
CC#CC(=O)N1CC[C@H](C1)n1cc(-c2ccc(Oc3c(F)cccc3F)cc2)c2c(N)n[nH]c(=O)c12
Target:
BTK

References

JIANGSU HENGRUI MEDICINE CO, et al. Pharmaceutically acceptable salt and crystal form of pyrrolo[2,3-d]pyridazin-7-one derivative and preparation method of medicinal salt and crystal form. WO2018210296A1.